Lea Naomi Eder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lea Naomi Eder has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arne Trummer
Department of Hematology and Oncology, Städtisches Klinikum Braunschweig, Braunschweig, Germany
1 shared publication - Christina Ganster
INDIGHO Laboratory, Department of Hematology and Medical Oncology, University Medical Center Göttingen (UMG), Göttingen, Germany
1 shared publication - Danilo Martinovic
Haematology and Medical Oncology University Medicine Göttingen Göttingen Germany
1 shared publication - Detlef Haase
Department of Hematology and Medical Oncology, INDIGHO laboratory, University Medical Center Göttingen (UMG), Göttingen, Germany
1 shared publication - Gerald Wulf
Clinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany
1 shared publication - Julia Thomson
Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 Göttingen, Germany
1 shared publication
Latest Publications
- Open Access
- 13 January 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (1) , 1146-1150
Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone.
- 13 January 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (1) , 1146-1150
Open AccessFatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone.